



FY 2023 FINANCIAL RESULTS

Disclaimer

This presentation (the “Presentation”) has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at <https://www.medacta.com/EN/investors>.

FORWARD-LOOKING INFORMATION

This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects”, “believes”, “estimates”, “targets”, “plans”, “outlook” or similar expressions.

There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this Presentation. The important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive

environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.

RELATED TRADEMARKS

Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts.

MyShoulder®, NextAR™, GMK® Sphere, MyKA™, GMK® SpheriKA, AMIS® , MySpine®

ALTERNATIVE PERFORMANCE MEASURES

This Presentation may contain information regarding alternative performance measures. Definitions of these measures and reconciliations between such measures and their IFRS counterparts if not defined in the Presentation may be found on the financial reports available on our website at <https://www.medacta.com/EN/investors>

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP


FRANCESCO SICCARDI

CHIEF EXECUTIVE OFFICER


FY 2023 KEY FIGURES

REVENUES EUR 510.8M

16.9% growth at reported currency (19.5% cc¹)
64.0% growth in constant currency from 2019




ADJUSTED EBITDA MARGIN³ EVOLUTION




EMPLOYEES 1'730

193 new jobs added in 2023



ADJUSTED EBITDA² EUR 134.2M 27.9% EBITDA MARGIN in cc 2022

(26.3% reported EBITDA margin)



1. Is calculated as the difference between the current and historical period results translated using the previous period exchange rates.
2. Is calculated as EBITDA, adjusted for non-recurring items: extraordinary legal and MDR expenses.
3. Adjusted EBITDA margin, is calculated as adjusted EBITDA as a percentage of Revenue for the period.




FY 2023 HIGHLIGHTS

- **FY 2023 revenue** increased to **EUR 510.8 million**, or **19.5% at constant currency** (16.9% reported) from FY 2022
- **Adjusted EBITDA** grew to **EUR 134.2 million** from EUR 120.4 million in 2022, corresponding to **27.9% margin in constant currency**, or 26.3% reported
- The Board of Directors is proposing a **distribution** of **CHF 0.55 per share** (0.54 CHF in 2022)
- **Outlook FY 2024:** We are targeting revenue growth at constant currency in the range of 13% to 15%, and Adjusted EBITDA margin at constant currency improving around 50 bps from 2023 reported, subject to unforeseen events.



FY 2023 REVENUE BRIDGE BY GEOGRAPHIC AREA¹




EMEA and APAC: a significant performance driven by all the Business lines.

North America: strong performance boosted by some patient backlog recovery in the first half of the year.

1. For a reconciliation of Alternative Performance Measures please refer to section headed "Alternative Performance Measures" of the Annual Report. The 2023 Annual Report is available at <https://www.medacta.com/EN/financial-reports>
 2. In 2023 we reorganized the key geographic areas introducing EMEA and LATAM regions, reclassifying Rest of the World (RoW) region. EMEA includes revenue from the former Europe region and certain countries originally included in RoW region. LATAM includes revenue from countries located in Latin America which were previously included in RoW region. 2022 figures have been restated accordingly

FY 2023 REVENUE BRIDGE BY PRODUCT LINE¹



Hip: good performance in all geographies mainly driven by Anterior Minimally Invasive Surgery Approach (AMIS) and Hip revision.

Knee: growth in every market thanks to a solid and complete product offering based on our personalized kinematic alignment solutions (MyKA).

Extremities: primarily attributable to Shoulder supported by Medacta Shoulder System and Technologies (MyShoulder and NextAR). Sportsmed business, which is in an early start-up phase, continued to develop its growth plan.

Spine: positive performance recorded in EMEA and North America. Growth in APAC was partially offset by price cuts in Japan. Good acceleration seen on the NextAR Spine utilization, recently supported by a clinical study which highlights its efficiency in spine surgery.



1. For a reconciliation of Alternative Performance Measures please refer to section headed "Alternative Performance Measures" of the Annual Report. The 2023 Annual Report is available at <https://www.medacta.com/EN/financial-reports>
 2. Extremities include Shoulder and Sportsmed revenues



CORRADO FARSETTA


CHIEF FINANCIAL OFFICER

FY 2023 P&L¹

PROFIT & LOSS STATEMENT (€m)	FY 2023	%	FY 2022	%	
Revenues	510.8	100.0%	437.1	100.0%	
Cost of Sales	(162.9)	-31.9%	(131.9)	-30.2%	
GROSS PROFIT	347.8	68.1%	305.3	69.8%	→ 69.6% c.c. (1.5% Fx effect)
<i>CORE R&D expenses</i>	(19.6)	-3.8%	(15.6)	-3.6%	
<i>CORE S&M expenses</i>	(186.7)	-36.5%	(159.6)	-36.5%	
<i>CORE G&A and other inc. and exp.</i>	(65.9)	-12.9%	(61.1)	-14.0%	
TOTAL CORE OPEX, out of which:	(272.1)	-53.3%	(236.3)	-54.1%	
Depreciation and Amortization	58.4	11.4%	51.5	11.8%	
Adjusted EBITDA²	134.2	26.3% ³	120.4	27.6%	→ 27.9% c.c.
Reported EBITDA	132.9	26.0%	113.0	25.8%	
Reported EBIT	74.4	14.6%	61.5	14.1%	
Financial Results	(15.7)	-3.1%	(6.7)	-1.5%	
PROFIT BEFORE TAXES	58.7	11.5%	54.8	12.5%	
Income Taxes	(11.4)	-2.2%	(8.5)	-2.0%	
PROFIT FOR THE PERIOD	47.4	9.3%	46.2	10.6%	



FY 2023 CAPEX FOR FUTURE GROWTH



	Var.	FY 2023	FY 2022
Investments (€M)	15.5	80.6	65.1
% of Reported Revenues	1%	16%	15%
% of Revenues cc growth	(25%)	94%	119%

FY 2023 FREE CASH FLOW

FREE CASH FLOW (€M)	FY 2023	FY 2022
CASH FLOW FROM OPERATING ACTIVITIES	75.1	73.5
CASH FLOW FROM INVESTING ACTIVITIES	(80.6)	(65.1)
FREE CASH FLOW	(5.5)	8.4

NET FINANCIAL DEBT¹



Notes:

1. For a reconciliation of Alternative Performance Measures please refer to section headed "Alternative Performance Measures" of the 2023 Annual Report. The 2023 Annual Report is available at <https://www.medacta.com/EN/investors>
2. Leverage calculated as Net Debt divided by EBITDA adjusted

FRANCESCO SICCARDI

CHIEF EXECUTIVE OFFICER

2024 OUTLOOK¹

We are targeting revenue growth at constant currency in the range of 13% to 15%, and Adjusted EBITDA margin at constant currency improving around 50 bps from 2023 reported, subject to unforeseen events.

Q&A



MEDACTA.COM